Specificities_NNS and_CC Opsonophagocytic_JJ Activities_NNS of_IN Antibodies_NNS to_TO Pneumococcal_NP Capsular_NP Polysaccharides_NP in_IN Sera_NP of_IN Unimmunized_NP Young_NP Children_NP An_DT enzyme_NN immunoassay_NN (_( EIA_NP )_) for_IN antibodies_NNS to_TO pneumococcal_JJ capsular_NN polysaccharides_NNS (_( Pnc_NP PSs_NP )_) detects_VBZ in_IN some_DT cases_NNS antibodies_NNS that_WDT are_VBP cross-reactive_JJ within_IN different_JJ Pnc_NP PSs_NP ._SENT Recently_RB ,_, it_PP has_VBZ been_VBN suggested_VBN that_IN for_IN detection_NN of_IN only_JJ serotype-specific_JJ antibodies_NNS ,_, EIA_NP can_MD be_VB modified_VBN by_IN removing_VBG cross-reactive_JJ antibodies_NNS by_IN absorption_NN with_IN an_DT irrelevant_JJ PS_NP ,_, e.g._FW ,_, the_DT type_NN 22F_NP PS_NP ._SENT The_DT opsonophagocytosis_NN assay_NN measures_VBZ the_DT functional_JJ activities_NNS of_IN antibodies_NNS in_IN vitro_NN ,_, and_CC the_DT results_NNS of_IN that_DT assay_NN correlate_NN with_IN in_IN vivo_JJ protection_NN better_RBR than_IN measurement_NN of_IN the_DT antibody_NN concentration_NN by_IN EIA_NP ._SENT We_PP compared_VBD these_DT different_JJ methods_NNS for_IN measuring_VBG antibodies_NNS to_TO type_NN 1_CD ,_, 6B_NP ,_, 11A_NP ,_, 14_CD ,_, 19F_NP ,_, and_CC 23F_NP Pnc_NP PSs_NP in_IN the_DT sera_NN of_IN unimmunized_JJ young_JJ children_NNS who_WP had_VBD been_VBN monitored_VBN for_IN pneumococcal_JJ carriage_NN ,_, acute_JJ otitis_NN media_NNS ,_, and_CC acquisition_NN of_IN antibodies_NNS to_TO Pnc_NP PSs_NP from_IN 2_CD to_TO 24_CD months_NNS of_IN age_NN ._SENT Serum_NN samples_NNS with_IN antibody_NN increases_NNS after_IN contact_NN with_IN a_DT pneumococcus_NN of_IN a_DT homologous_JJ serotype_NN contained_VBD specific_JJ antibodies_NNS and_CC often_RB had_VBD opsonophagocytic_JJ activity_NN (_( OPA_NP )_) (_( 20_CD of_IN 46_CD )_) ._SENT In_IN samples_NNS with_IN antibody_NN increases_NNS from_IN children_NNS who_WP had_VBD not_RB had_VBN contact_NN with_IN a_DT pneumococcus_NN of_IN a_DT homologous_JJ serotype_NN ,_, the_DT antibodies_NNS found_VBD to_TO be_VB type_NN specific_JJ by_IN conventional_JJ EIA_NP were_VBD usually_RB cross-reactive_JJ and_CC infrequently_RB had_VBD OPA_NP (_( 10_CD of_IN 68_CD )_) ._SENT When_WRB type_NN 22F_JJ PS_NP absorption_NN was_VBD used_VBN in_IN the_DT EIA_NP ,_, most_JJS of_IN the_DT false_JJ antibody_NN increases_NNS were_VBD eliminated_VBN ,_, but_CC most_JJS of_IN the_DT true_JJ antibody_NN increases_NNS were_VBD still_RB detected_VBN and_CC the_DT association_NN between_IN the_DT antibody_NN concentration_NN detected_VBN by_IN EIA_NP and_CC OPA_NP was_VBD improved_VBN ._SENT However_RB ,_, there_EX were_VBD serotype-dependent_JJ differences_NNS in_IN the_DT frequency_NN of_IN OPA_NP ._SENT Use_NN of_IN absorption_NN with_IN a_DT heterologous_JJ PS_NP in_IN EIA_NP should_MD be_VB encouraged_VBN ,_, and_CC both_CC the_DT specificity_NN of_IN EIA_NP and_CC the_DT sensitivity_NN of_IN opsonophagocytic_JJ assays_NNS should_MD be_VB further_RBR evaluated_VBN and_CC improved_VBN ._SENT Immunity_NN against_IN Streptococcus_NP pneumoniae_NNS (_( pneumococcus_NN )_) is_VBZ mediated_VBN by_IN phagocytosis_NN in_IN the_DT presence_NN of_IN complement_NN and_CC antibodies_NNS to_TO pneumococcal_JJ capsular_NN polysaccharides_NNS (_( Pnc_NP PSs_NP )_) ._SENT The_DT in_IN vitro_NP opsonophagocytic_JJ activities_NNS (_( OPAs_NP )_) of_IN serum_NN antibodies_NNS are_VBP believed_VBN to_TO represent_VB the_DT functional_JJ activities_NNS of_IN the_DT antibodies_NNS in_IN vivo_JJ and_CC thus_RB to_TO correlate_VB with_IN protective_JJ immunity_NN ._SENT Enzyme_NN immunoassay_NN (_( EIA_NP )_) for_IN the_DT measurement_NN of_IN the_DT concentrations_NNS of_IN antibodies_NNS to_TO Pnc_NP PSs_NP has_VBZ been_VBN widely_RB used_VBN to_TO measure_VB immunity_NN to_TO pneumococci_NNS and_CC the_DT immunogenicities_NNS of_IN pneumococcal_JJ vaccines_NNS ._SENT However_RB ,_, for_IN the_DT estimation_NN of_IN immunity_NN ,_, a_DT good_JJ correlation_NN between_IN the_DT concentration_NN of_IN immunoglobulin_NN G_NP (_( IgG_NP )_) measured_VBD by_IN EIA_NP and_CC the_DT OPAs_NP of_IN antibodies_NNS is_VBZ needed_VBN ._SENT The_DT correlation_NN between_IN the_DT two_CD methods_NNS has_VBZ been_VBN reasonably_RB good_JJ with_IN postimmunization_NN serum_NN samples_NNS from_IN infants_NNS and_CC adults_NNS ._SENT However_RB ,_, sera_NN from_IN unimmunized_JJ individuals_NNS may_MD have_VB lower_JJR OPAs_NNS than_IN expected_VBN on_IN the_DT basis_NN of_IN the_DT antibody_NN concentration_NN obtained_VBN by_IN EIA_NP ._SENT The_DT Pnc_NP PS_NP preparations_NNS used_VBN in_IN the_DT present_JJ EIAs_NNS are_VBP contaminated_VBN with_IN a_DT common_JJ cell_NN wall_NN PS_NP (_( CPS_NP )_) ,_, and_CC antibodies_NNS to_TO CPS_NP should_MD be_VB absorbed_VBN to_TO improve_VB the_DT specificity_NN of_IN the_DT EIA_NP ._SENT Recently_RB ,_, several_JJ investigators_NNS have_VBP reported_VBN that_IN despite_IN absorption_NN with_IN CPS_NP ,_, antibodies_NNS cross-reactive_JJ with_IN several_JJ types_NNS of_IN Pnc_NP PSs_NP are_VBP still_RB measured_VBN by_IN EIA_NP ._SENT The_DT reason_NN for_IN this_DT cross-reactivity_NN has_VBZ not_RB been_VBN confirmed_VBN ._SENT It_PP has_VBZ been_VBN suggested_VBN that_IN the_DT Pnc_NP PS_NP preparations_NNS used_VBN as_IN EIA_NP antigens_NNS contain_VBP impurities_NNS or_CC cross-reactive_JJ epitopes_NNS common_JJ to_TO many_JJ serotypes_NNS ._SENT Removal_NN of_IN the_DT cross-reactive_JJ antibodies_NNS by_IN absorption_NN with_IN an_DT irrelevant_JJ heterologous_JJ PS_NP ,_, e.g._FW ,_, the_DT type_NN 22F_NP PS_NP ,_, improves_VBZ the_DT correlation_NN between_IN the_DT antibody_NN concentration_NN obtained_VBN by_IN EIA_NP and_CC the_DT OPA_NP ._SENT Thus_RB ,_, type_NN 22F_NP PS_NP absorption_NN has_VBZ been_VBN suggested_VBN as_IN an_DT additional_JJ step_NN in_IN EIAs_NNS for_IN antibodies_NNS to_TO Pnc_NP PSs_NP ._SENT Cross-reactive_JJ antibodies_NNS are_VBP found_VBN more_RBR often_RB in_IN the_DT sera_NN of_IN unimmunized_JJ infants_NNS and_CC adults_NNS than_IN in_IN the_DT sera_NN of_IN infants_NNS and_CC adults_NNS immunized_VBN with_IN pneumococcal_JJ vaccines_NNS ,_, suggesting_VBG that_IN the_DT majority_NN of_IN the_DT antibodies_NNS induced_VBN by_IN vaccination_NN are_VBP Pnc_NP PS_NP type_NN or_CC group_NN specific_NN ._SENT The_DT origin_NN and_CC development_NN of_IN the_DT cross-reactive_JJ antibodies_NNS by_IN age_NN has_VBZ not_RB been_VBN studied_VBN ._SENT We_PP have_VBP previously_RB described_VBN the_DT natural_JJ development_NN of_IN antibodies_NNS to_TO Pnc_NP PSs_NP ,_, as_RB detected_VBN by_IN EIA_NP ,_, during_IN the_DT first_JJ 2_CD years_NNS of_IN life_NN ,_, and_CC antibody_NN responses_NNS in_IN children_NNS with_IN pneumococcal_JJ acute_JJ otitis_NN media_NNS (_( AOM_NP )_) in_IN a_DT Finnish_JJ Otitis_NP Media_NP (_( FinOM_NP )_) Cohort_NP Study_NP ._SENT Pneumococcal_JJ carriage_NN and_CC AOM_NP induced_VBD antibodies_NNS to_TO the_DT homologous_JJ Pnc_NP PS_NP ,_, but_CC there_EX were_VBD serotype-specific_JJ differences_NNS ._SENT Low_JJ concentrations_NNS of_IN antibodies_NNS were_VBD also_RB produced_VBN after_IN contact_NN with_IN pneumococci_NNS with_IN heterologous_JJ serotypes_NNS and_CC even_RB with_IN no_DT detectable_JJ contact_NN with_IN pneumococci_NNS ._SENT In_IN this_DT study_NN ,_, we_PP evaluated_VBD the_DT specificities_NNS and_CC OPAs_NNS of_IN antibodies_NNS in_IN selected_JJ serum_NN samples_NNS from_IN our_PP$ previous_JJ study_NN ._SENT We_PP used_VBD a_DT set_NN of_IN samples_NNS that_WDT had_VBD twofold_JJ or_CC greater_JJR increases_NNS in_IN antibody_NN concentrations_NNS compared_VBN to_TO the_DT concentration_NN in_IN a_DT sample_NN taken_VBN 6_CD months_NNS earlier_RBR and_CC with_IN approximately_RB 1_CD mug_NN or_CC more_JJR of_IN anti-Pnc_NP PS_NP antibodies_NNS per_IN ml_NN ,_, as_RB measured_VBN by_IN the_DT conventional_JJ EIA_NP ._SENT Such_JJ samples_NNS were_VBD selected_VBN from_IN children_NNS with_IN and_CC without_IN a_DT previous_JJ contact_NN with_IN pneumococci_NNS of_IN the_DT homologous_JJ serotype_NN ._SENT The_DT effect_NN of_IN the_DT type_NN 22F_JJ PS_NP absorption_NN step_NN in_IN the_DT EIA_NP was_VBD also_RB evaluated_VBN ._SENT Study_NN population_NN and_CC sera_NN ._SENT |_SYM Serum_NP samples_NNS for_IN this_DT study_NN were_VBD selected_VBN from_IN among_IN the_DT samples_NNS from_IN participants_NNS in_IN the_DT FinOM_NP Cohort_NP Study_NP used_VBD in_IN our_PP$ previous_JJ study_NN ._SENT The_DT study_NN population_NN consisted_VBN of_IN 329_CD healthy_JJ Finnish_JJ children_NNS who_WP were_VBD monitored_VBN prospectively_RB in_IN a_DT special_JJ study_NN clinic_NN from_IN 2_CD to_TO 24_CD months_NNS of_IN age_NN ._SENT During_IN scheduled_VBN visits_NNS at_IN 2_CD ,_, 3_CD ,_, 4_CD ,_, 5_CD ,_, 6_CD ,_, 9_CD ,_, 12_CD ,_, 15_CD ,_, 18_CD ,_, and_CC 24_CD months_NNS of_IN age_NN ,_, interview_NN data_NNS and_CC nasopharyngeal_JJ (_( NP_NP )_) swab_NN specimens_NNS for_IN detection_NN of_IN pneumococcal_JJ carriage_NN were_VBD obtained_VBN ._SENT In_IN addition_NN ,_, NP_NP aspirates_NNS (_( NPAs_NP )_) and_CC middle_JJ ear_NN fluid_NN (_( MEF_NP )_) samples_NNS were_VBD obtained_VBN from_IN patients_NNS with_IN respiratory_JJ infection_NN and_CC from_IN patients_NNS with_IN a_DT diagnosis_NN of_IN AOM_NP ,_, respectively_RB ._SENT Serum_NP samples_NNS (_( 5_CD ml_NN of_IN venous_JJ blood_NN )_) were_VBD obtained_VBN from_IN the_DT children_NNS at_IN scheduled_VBN visits_NNS at_IN 6_CD (_( +-14_NN days_NNS )_) ,_, 12_CD (_( +-14_NN days_NNS )_) ,_, 18_CD (_( +-28_NN days_NNS )_) ,_, and_CC 24_CD (_( +-28_NN days_NNS )_) months_NNS of_IN age_NN ._SENT The_DT sera_NN were_VBD stored_VBN at_IN -20C_NN ._SENT The_DT NP_NP swabs_NNS ,_, NPAs_NP ,_, and_CC MEF_NP samples_NNS were_VBD collected_VBN and_CC cultured_VBN as_IN described_VBN previously_RB for_IN detection_NN of_IN pneumococcal_JJ carriage_NN or_CC the_DT etiology_NN of_IN AOM_NP ._SENT Pneumococci_NNS were_VBD identified_VBN and_CC serotyped_VBN by_IN standard_JJ methods_NNS ._SENT The_DT development_NN of_IN antibodies_NNS by_IN age_NN has_VBZ been_VBN reported_VBN earlier_RBR ._SENT Serum_NN samples_NNS used_VBN in_IN this_DT study_NN ._SENT |_SYM Selected_JJ serum_NN samples_NNS taken_VBN at_IN the_DT scheduled_VBN visits_NNS at_IN 18_CD or_CC 24_CD months_NNS of_IN age_NN were_VBD used_VBN in_IN this_DT study_NN ._SENT The_DT following_VBG criteria_NNS were_VBD used_VBN for_IN selection_NN :_: a_DT twofold_JJ or_CC greater_JJR increase_NN in_IN the_DT concentration_NN of_IN antibody_NN to_TO PS_NP of_IN type_NN 1_CD ,_, 6B_NP ,_, 11A_NP ,_, 14_CD ,_, 19F_NP ,_, or_CC 23F_NN compared_VBN to_TO the_DT concentration_NN in_IN the_DT sample_NN taken_VBN during_IN the_DT previous_JJ scheduled_JJ visit_NN (_( i.e._FW ,_, at_IN 12_CD or_CC 18_CD months_NNS ,_, respectively_RB )_) and_CC the_DT presence_NN of_IN an_DT antibody_NN concentration_NN of_IN approximately_RB 1_CD mug/ml_NN or_CC greater_JJR ._SENT An_DT antibody_NN concentration_NN of_IN at_IN least_JJS 1_CD mug/ml_NN is_VBZ needed_VBN to_TO achieve_VB detectable_JJ OPA_NP in_IN infant_JJ sera_NN taken_VBN after_IN vaccination_NN ._SENT The_DT serum_NN samples_NNS were_VBD further_RBR grouped_VBN according_VBG to_TO pneumococcal_JJ culture_NN findings_NNS ._SENT Sera_NN in_IN the_DT Pnc_NP PS_NP contact-positive_NP (_( Pnc_NP 6B+_NP ,_, Pnc_NP 11A+_NP ,_, Pnc_NP 14+_NP ,_, Pnc_NP 19F+_NP ,_, and_CC Pnc_NP 23F+_NP )_) groups_NNS were_VBD from_IN children_NNS who_WP had_VBD had_VBN at_IN least_JJS one_CD culture-confirmed_JJ contact_NN with_IN a_DT pneumococcus_NN of_IN the_DT indicated_JJ serotype_NN (_( pneumococci_NNS of_IN that_DT serotype_NN were_VBD cultured_VBN from_IN NP_NP swabs_NNS ,_, NPAs_NP ,_, and/or_CC MEF_NP samples_NNS )_) between_IN the_DT two_CD scheduled_JJ visits_NNS ._SENT Accordingly_RB ,_, sera_NN in_IN the_DT Pnc_NP PS_NP contact-negative_NP (_( Pnc_NP 1-_CD ,_, Pnc_NP 6B-_NP ,_, Pnc_NP 11A-_NP ,_, Pnc_NP 14-_CD ,_, Pnc_NP 19F-_NP ,_, and_CC Pnc_NP 23F-_NP )_) groups_NNS were_VBD from_IN children_NNS who_WP had_VBD not_RB had_VBN any_DT detectable_JJ contact_NN with_IN the_DT respective_JJ serotype_NN by_IN the_DT indicated_JJ age_NN ,_, despite_IN the_DT increase_NN in_IN antibody_NN concentrations_NNS ._SENT These_DT children_NNS may_MD have_VB had_VBN contacts_NNS with_IN other_JJ pneumococcal_JJ serotypes_NNS or_CC no_DT contacts_NNS with_IN pneumococci_NNS at_IN all_DT ._SENT Data_NNS were_VBD derived_VBN from_IN a_DT total_NN of_IN 82_CD serum_NN samples_NNS from_IN 75_CD children_NNS ._SENT Some_DT samples_NNS were_VBD included_VBN more_RBR than_IN once_RB ._SENT PSs_NP ._SENT |_SYM Capsular_NP PSs_NP of_IN S._NP pneumoniae_NP serotypes_NNS 1_CD (_( lot_NN 1211368_CD )_) ,_, 11A_NP (_( lot_NN 963596_CD )_) ,_, 14_CD (_( lot_NN 2020510_CD )_) ,_, 19F_NP (_( lot_NN 2033178_CD )_) ,_, 22F_JJ (_( lots_NNS 1450702_CD and_CC 2045906_CD )_) ,_, and_CC 23F_JJ (_( lot_NN 1417200_CD )_) were_VBD obtained_VBN from_IN American_NP Type_NP Culture_NP Collection_NP (_( ATCC_NP ;_: Manassas_NP ,_, Va._NP )_) ._SENT Capsular_NN PS_NP of_IN serotype_NP 6B_NP was_VBD received_VBN via_IN collaboration_NN with_IN the_DT National_NP Institute_NP of_IN Public_NP Health_NP and_CC the_DT Environment_NP (_( Bilthoven_NP ,_, The_DT Netherlands_NPS )_) ._SENT The_DT CPS_NP used_VBD for_IN absorption_NN of_IN anti-CPS_NNS antibodies_NNS from_IN the_DT sera_NN was_VBD from_IN the_DT Statens_NP Serum_NP Institut_NP (_( Copenhagen_NP ,_, Denmark_NP )_) ._SENT EIA_NP ._SENT |_SYM The_DT conventional_JJ EIA_NP was_VBD performed_VBN as_IN described_VBN earlier_RBR by_IN Kayhty_NP et_FW al._FW ._SENT The_DT results_NNS are_VBP expressed_VBN as_IN micrograms_NNS per_IN milliliter_NN ,_, calculated_VBN on_IN the_DT basis_NN of_IN the_DT officially_RB assigned_VBN IgG_NP concentrations_NNS in_IN reference_NN serum_NN sample_NN 89-SF_NN ._SENT In_IN addition_NN to_TO the_DT conventional_JJ EIA_NP ,_, antibody_NN concentrations_NNS were_VBD determined_VBN by_IN EIA_NP with_IN an_DT absorption_NN step_NN with_IN type_NN 22F_NP PS_NP ;_: the_DT lowest_JJS serum_NN dilution_NN was_VBD incubated_VBN with_IN 10_CD mug_NN of_IN CPS_NP per_IN ml_NN and_CC 30_CD mug_NN of_IN type_NN 22F_NP PS_NP per_IN ml_NN for_IN 1_CD h_NN at_IN room_NN temperature_NN before_IN the_DT EIA_NP ._SENT The_DT interassay_NN coefficient_NN of_IN variance_NN for_IN both_DT EIA_NP methods_NNS was_VBD <15_JJ %_NN ._SENT Inhibition_NN EIA_NP ._SENT |_SYM Serum_NP samples_NNS were_VBD diluted_VBN 1:100_CD in_IN 10_CD %_NN fetal_JJ bovine_JJ serum_NN (_( Life_NP Technologies_NP ,_, Ltd._NP ,_, Paisley_NP ,_, Scotland_NP )_) in_IN phosphate-buffered_JJ saline_NN containing_VBG 10_CD mug_NN of_IN CPS_NP per_IN ml_NN and_CC aliquoted_JJ and_CC placed_VBN into_IN three_CD separate_JJ tubes_NNS ._SENT Either_CC homologous_JJ (_( type_NN 1_CD ,_, 6B_NP ,_, 11A_NP ,_, 14_CD ,_, 19F_NP ,_, or_CC 23F_JJ )_) or_CC heterologous_JJ (_( type_NN 22F_NN )_) Pnc_NP PS_NP (_( 30_CD mug/ml_NN )_) was_VBD added_VBN ,_, and_CC the_DT tubes_NNS were_VBD incubated_VBN for_IN 1_CD h_NN at_IN room_NN temperature_NN ._SENT A_DT control_NN tube_NN containing_VBG only_JJ CPS_NP was_VBD included_VBN ._SENT The_DT concentration_NN of_IN 30_CD mug/ml_NN was_VBD found_VBN to_TO be_VB optimal_JJ for_IN absorption_NN for_IN the_DT PS_NP types_NNS studied_VBD ._SENT After_IN absorption_NN ,_, EIA_NP was_VBD performed_VBN as_IN described_VBN above_IN ._SENT The_DT percent_NN inhibition_NN was_VBD calculated_VBN from_IN the_DT optical_JJ density_NN values_NNS ._SENT Inhibition_NN of_IN antibody_NN binding_VBG by_IN <=20%_was =80_JJ %_NN was_VBD considered_VBN effective_JJ ._SENT Opsonophagocytosis_NN assay_NN ._SENT |_SYM The_DT OPAs_NP of_IN the_DT antibodies_NNS were_VBD analyzed_VBN by_IN measuring_VBG the_DT killing_NN of_IN live_JJ pneumococci_NNS by_IN differentiated_VBN HL-60_JJ cells_NNS in_IN the_DT presence_NN of_IN serum_NN antibody_NN and_CC complement_NN ._SENT A_DT modification_NN of_IN the_DT method_NN described_VBN by_IN Romero-Steiner_NP et_FW al._FW was_VBD used_VBN ._SENT S._NP pneumoniae_NP serotypes_NNS 1_CD ,_, 6B_JJ ,_, 14_CD ,_, 19F_NP ,_, and_CC 23F_JJ (_( reference_NN strains_NNS received_VBN from_IN the_DT Centers_NPS for_IN Disease_NP Control_NP and_CC Prevention_NP ,_, Atlanta_NP ,_, Ga._NP )_) and_CC serotype_NP 11A_NP (_( reference_NN strain_NN obtained_VBN from_IN the_DT World_NP Health_NP Organization_NP Collaborating_NP Center_NP for_IN Reference_NP and_CC Research_NP on_IN Streptococci_NP ,_, Prague_NP ,_, Czech_NP Republic_NP )_) were_VBD grown_VBN in_IN Todd-Hewitt_NP broth_NN supplemented_VBD with_IN 0.5_CD %_NN yeast_NN extract_NN and_CC kept_VBD frozen_JJ (_( -70C_NN )_) in_IN aliquots_NNS in_IN Todd-Hewitt_NP broth_NN with_IN 15_CD %_NN glycerol_NN ._SENT OPA_NP is_VBZ expressed_VBN as_IN a_DT titer_NN that_WDT is_VBZ the_DT reciprocal_NN of_IN the_DT serum_NN dilution_NN with_IN 50_CD %_NN killing_NN compared_VBN with_IN the_DT bacterial_JJ growth_NN in_IN the_DT controls_NNS without_IN serum_NN ._SENT A_DT titer_NN of_IN 4_CD was_VBD given_VBN to_TO sera_NN with_IN undetectable_JJ OPAs_NP ._SENT To_TO demonstrate_VB the_DT specificities_NNS of_IN opsonic_JJ antibodies_NNS ,_, serum_NN samples_NNS were_VBD preincubated_VBN with_IN either_DT CPS_NP or_CC homologous_JJ or_CC heterologous_JJ Pnc_NP PS_NP (_( 30_CD min_NN at_IN room_NN temperature_NN with_IN 1_CD mg_NN of_IN PS_NP or_CC CPS_NP in_IN 1_CD ml_NN of_IN undiluted_JJ sera_NN )_) prior_RB to_TO the_DT assay_NN for_IN OPA_NP ._SENT OPA_NP was_VBD totally_RB removed_VBN only_RB from_IN samples_NNS preincubated_VBN with_IN the_DT homologous_JJ Pnc_NP PS_NP ._SENT Statistical_JJ analyses_NNS ._SENT |_SYM The_DT average_JJ antibody_NN concentrations_NNS were_VBD expressed_VBN as_IN geometric_JJ mean_JJ concentrations_NNS (_( GMCs_NP )_) and_CC the_DT average_JJ OPAs_NP were_VBD expressed_VBN as_IN geometric_JJ mean_NN OPAs_NP (_( GMOPAs_NP )_) ._SENT TABLE_NN 1_CD |_SYM Selection_NN of_IN serum_NN samples_NNS from_IN among_IN the_DT FinOM_NP Cohort_NP Study_NP samples_NNS for_IN the_DT different_JJ groups_NNS In_IN the_DT whole_JJ FinOM_NP Cohort_NP Study_NP population_NN ,_, the_DT number_NN of_IN serum_NN samples_NNS with_IN twofold_JJ or_CC greater_JJR increases_NNS in_IN antibody_NN concentrations_NNS that_WDT yielded_VBD an_DT approximately_RB 1_CD mug/ml_NN or_CC higher_JJR concentration_NN in_IN the_DT sample_NN obtained_VBN at_IN 18_CD or_CC 24_CD months_NNS of_IN age_NN depended_VBN on_IN the_DT serotype_NN ._SENT Among_IN the_DT serum_NN samples_NNS from_IN children_NNS without_IN a_DT previous_JJ contact_NN with_IN the_DT homologous_JJ serotype_NN ,_, increases_NNS in_IN the_DT concentrations_NNS of_IN antibodies_NNS to_TO type_NN 1_CD ,_, 6B_NP ,_, 11A_NP ,_, 14_CD ,_, and_CC 23F_NP PSs_NP were_VBD detected_VBN in_IN 4_CD to_TO 9_CD %_NN of_IN serum_NN samples_NNS and_CC increases_NNS in_IN the_DT concentrations_NNS of_IN antibodies_NNS to_TO type_NN 19F_NP PS_NP were_VBD detected_VBN in_IN 20_CD %_NN of_IN the_DT serum_NN samples_NNS ._SENT Among_IN the_DT children_NNS with_IN antibody_NN increases_NNS but_CC without_IN contact_NN with_IN homologous_JJ type_NN 1_CD ,_, 6B_NP ,_, 11A_NP ,_, 14_CD ,_, 19F_NP ,_, or_CC 23F_JJ pneumococci_NNS ,_, 8_CD of_IN 13_CD ,_, 7_CD of_IN 8_CD ,_, 16_CD of_IN 20_CD ,_, 7_CD of_IN 10_CD ,_, 20_CD of_IN 34_CD ,_, and_CC 5_CD of_IN 12_CD ,_, respectively_RB ,_, had_VBD had_VBN contact_NN with_IN other_JJ serotypes_NNS of_IN pneumococci_NNS ._SENT Antibody_NN increases_NNS occurred_VBD more_JJR frequently_RB (_( 11_CD to_TO 70_CD %_NN )_) in_IN children_NNS with_IN contact_NN with_IN a_DT homologous_JJ serotype_NN ._SENT Specificities_NNS of_IN antibodies_NNS and_CC effect_NN of_IN type_NN 22F_JJ PS_NP absorption_NN on_IN the_DT antibody_NN concentration_NN measured_VBN by_IN EIA_NP ._SENT |_SYM The_DT specificities_NNS of_IN antibodies_NNS to_TO serotypes_NNS 1_CD ,_, 6B_NP ,_, 11A_NP ,_, 14_CD ,_, 19F_NP ,_, and_CC 23F_NN measured_VBN by_IN EIA_NP were_VBD analyzed_VBN by_IN inhibition_NN of_IN antibody_NN binding_VBG with_IN the_DT homologous_JJ PS_NP (_( type_NN 1_CD ,_, 6B_NP ,_, 11A_NP ,_, 14_CD ,_, 19F_NP ,_, or_CC 23F_JJ )_) or_CC a_DT heterologous_JJ PS_NP (_( type_NN 22F_NN )_) ._SENT Serotype-specific_JJ antibodies_NNS were_VBD considered_VBN those_DT that_WDT were_VBD not_RB inhibited_VBN (_( <20%)_by 80_CD %_NN )_) by_IN the_DT homologous_JJ PS_NP ._SENT Cross-reactive_JJ ,_, nonspecific_JJ antibodies_NNS were_VBD inhibited_VBN (_( >20_JJ %_NN )_) by_IN heterologous_JJ PS_NP ._SENT The_DT antibodies_NNS to_TO serotypes_NNS 6B_JJ and_CC 14_CD in_IN the_DT serum_NN samples_NNS from_IN the_DT Pnc_NP 6B+_JJ and_CC Pnc_JJ 14+_JJ groups_NNS were_VBD highly_RB specific_JJ ._SENT In_IN most_JJS cases_NNS the_DT level_NN of_IN inhibition_NN by_IN heterologous_JJ PSs_NP was_VBD <20%,_and 80_CD %_NN ._SENT Furthermore_RB ,_, they_PP were_VBD mainly_RB inhibited_VBN only_RB by_IN the_DT homologous_JJ PSs_NP :_: >80_JJ %_NN inhibition_NN by_IN homologous_JJ PSs_NP was_VBD seen_VBN in_IN three_CD of_IN four_CD and_CC five_CD of_IN six_CD serum_NN samples_NNS ,_, respectively_RB ._SENT However_RB ,_, poorer_JJR inhibition_NN by_IN homologous_JJ PSs_NP was_VBD found_VBN in_IN the_DT serum_NN samples_NNS from_IN the_DT Pnc_NP 6B-_NP and_CC Pnc_NP 14-_CD groups_NNS ._SENT It_PP should_MD be_VB noted_VBN that_IN three_CD of_IN the_DT eight_CD serum_NN samples_NNS in_IN the_DT Pnc_NP 6B-_JJ group_NN were_VBD from_IN children_NNS who_WP had_VBD had_VBN contact_NN with_IN serotype_NN 6A_NN ,_, and_CC in_IN two_CD of_IN the_DT three_CD serum_NN samples_VBZ the_DT antibodies_NNS to_TO PS_NP type_NN 6B_NN were_VBD specific_JJ ._SENT Consequently_RB ,_, in_IN all_DT groups_NNS the_DT concentrations_NNS of_IN antibodies_NNS to_TO type_VB 6B_JJ and_CC type_NN 14_NP PSs_NP obtained_VBD either_RB by_IN the_DT conventional_JJ EIA_NP or_CC by_IN EIA_NP with_IN the_DT type_NN 22F_JJ PS_NP absorption_NN step_NN were_VBD equal_JJ ;_: in_IN addition_NN ,_, neither_CC the_DT GMCs_NP nor_CC the_DT antibody_NN concentrations_NNS in_IN the_DT individual_JJ serum_NN samples_NNS (_( data_NNS not_RB shown_VBN )_) were_VBD affected_VBN by_IN the_DT use_NN of_IN type_NN 22F_JJ PS_NP absorption_NN ._SENT Antibodies_NNS to_TO serotype_NP 11A_NP were_VBD highly_RB specific_JJ in_IN the_DT Pnc_NP 11A+_JJ group_NN :_: heterologous_JJ inhibition_NN of_IN <20%_was 80_CD %_NN was_VBD detected_VBN in_IN 15_CD of_IN the_DT 16_CD serum_NN samples_NNS ._SENT In_IN the_DT Pnc_NP 11A-_JJ group_NN ,_, however_RB ,_, heterologous_JJ inhibition_NN of_IN >20_JJ %_NN was_VBD detected_VBN in_IN 9_CD of_IN 17_CD serum_NN samples_NNS ._SENT Consequently_RB ,_, the_DT EIA_NP with_IN type_NN 22F_JJ PS_NP absorption_NN gave_VBD lower_JJR antibody_NN concentrations_NNS than_IN the_DT conventional_JJ EIA_NP for_IN the_DT Pnc_NP 11A-_JJ group_NN but_CC not_RB the_DT Pnc_NP 11A+_JJ group_NN ._SENT Very_RB similar_JJ observations_NNS were_VBD made_VBN for_IN serotype_NN 23F_NN :_: antibodies_NNS were_VBD specific_JJ in_IN the_DT Pnc_NP 23F+_JJ group_NN but_CC mostly_RB cross-reactive_JJ in_IN the_DT Pnc_NP 23F-_JJ group_NN ._SENT The_DT type_NN 22F_JJ PS_NP absorption_NN step_NN in_IN EIA_NP markedly_RB reduced_VBD the_DT concentrations_NNS of_IN antibodies_NNS to_TO type_NN 23F_NP PS_NP in_IN the_DT Pnc_NP 23F-_JJ group_NN but_CC not_RB the_DT Pnc_NP 23F+_JJ group_NN ._SENT Antibodies_NNS to_TO type_NN 19F_NP PS_NP had_VBD a_DT complex_JJ pattern_NN ._SENT The_DT specificities_NNS of_IN the_DT antibodies_NNS were_VBD somewhat_RB better_JJR in_IN the_DT Pnc_NP 19F+_JJ group_NN than_IN in_IN the_DT Pnc_NP 19F-_JJ group_NN ;_: 7_CD of_IN 13_CD and_CC 4_CD of_IN 13_CD serum_NN samples_NNS ,_, respectively_RB ,_, were_VBD specific_JJ and_CC were_VBD not_RB inhibited_VBN (_( >20_JJ %_NN )_) by_IN the_DT heterologous_JJ PS_NP ._SENT However_RB ,_, many_JJ serum_NN samples_NNS showed_VBD antibody_NN binding_NN that_WDT could_MD not_RB be_VB effectively_RB (_( >80_JJ %_NN )_) inhibited_VBD by_IN either_DT type_NN 19F_NN or_CC type_NN 22F_NP PS_NP ._SENT All_PDT the_DT serum_NN samples_NNS from_IN the_DT Pnc_NP 19F-_JJ group_NN had_VBD antibodies_NNS with_IN poor_JJ specificities_NNS ;_: 5_CD were_VBD effectively_RB (_( >80_JJ %_NN )_) inhibited_VBN by_IN heterologous_JJ PS_NP ,_, in_IN addition_NN to_TO the_DT type_NN 19F_NP PS_NP ,_, and_CC in_IN 5_CD additional_JJ serum_NN samples_NNS the_DT level_NN of_IN inhibition_NN by_IN either_CC the_DT homologous_JJ PS_NP or_CC the_DT heterologous_JJ PS_NP was_VBD low_JJ ._SENT The_DT EIA_NP with_IN the_DT type_NN 22F_JJ PS_NP absorption_NN step_NN gave_VBD lower_JJR concentrations_NNS than_IN the_DT conventional_JJ EIA_NP for_IN both_CC the_DT Pnc_NP 19F-_NP and_CC Pnc_NP 19F+_JJ groups_NNS ._SENT However_RB ,_, the_DT difference_NN was_VBD more_RBR remarkable_JJ in_IN the_DT Pnc_NP 19F-_JJ group_NN ._SENT Serotype_NP 1_CD was_VBD not_RB cultured_VBN from_IN any_DT of_IN the_DT samples_NNS during_IN the_DT study_NN ._SENT In_IN spite_NN of_IN this_DT ,_, 13_CD children_NNS had_VBD increased_VBN levels_NNS of_IN antibodies_NNS to_TO the_DT type_NN 1_CD Pnc_NP PS_NP ,_, as_RB measured_VBN by_IN conventional_JJ EIA_NP ._SENT The_DT antibodies_NNS to_TO serotype_NN 1_CD were_VBD not_RB specific_JJ :_: inhibition_NN by_IN the_DT homologous_JJ serotype_NN as_RB well_RB as_IN inhibition_NN by_IN the_DT heterologous_JJ serotype_NN was_VBD >80_JJ %_NN for_IN all_DT serum_NN samples_NNS ._SENT The_DT EIA_NP with_IN type_NN 22F_JJ PS_NP absorption_NN detected_VBD practically_RB no_DT antibodies_NNS to_TO the_DT type_NN 1_CD Pnc_NP PS_NP ._SENT OPAs_NNS of_IN antibodies_NNS ._SENT |_SYM Higher_NP OPAs_NP against_IN pneumococci_NNS of_IN serotypes_NNS 6B_JJ ,_, 11A_NP ,_, 14_CD ,_, and_CC 23F_NP were_VBD measured_VBN in_IN the_DT sera_NN of_IN children_NNS taken_VBN after_IN contact_NN with_IN a_DT homologous_JJ serotype_NN than_IN in_IN the_DT sera_NN of_IN children_NNS with_IN no_DT contact_NN with_IN a_DT homologous_JJ serotype_NN ._SENT Even_RB though_IN the_DT concentrations_NNS of_IN specific_JJ antibodies_NNS (_( determined_VBN by_IN EIA_NP with_IN type_NN 22F_JJ PS_NP absorption_NN )_) to_TO type_VB 6B_JJ and_CC type_NN 14_NP PSs_NP were_VBD equal_JJ ,_, the_DT OPAs_NP were_VBD higher_JJR and_CC were_VBD found_VBN more_RBR frequently_RB in_IN the_DT Pnc_NP 6B+_JJ and_CC Pnc_JJ 14+_JJ groups_NNS than_IN in_IN the_DT Pnc_NP 6B-_NP and_CC Pnc_NP 14-_CD groups_NNS ._SENT Although_IN most_RBS (_( 16_CD of_IN 26_CD )_) of_IN the_DT serum_NN samples_NNS in_IN the_DT Pnc_NP 19F+_JJ and_CC 19F-_JJ groups_NNS had_VBD concentrations_NNS of_IN antibodies_NNS to_TO type_NN 19F_NP PS_NP of_IN >=1_JJ mug/ml_NN ,_, as_RB measured_VBN by_IN EIA_NP with_IN type_NN 22F_JJ absorption_NN ,_, none_NN of_IN the_DT samples_NNS had_VBD OPAs_NNS against_IN the_DT type_NN 19F_NN strain_NN ._SENT Antibodies_NNS to_TO the_DT type_NN 1_CD PS_NP were_VBD removed_VBN from_IN all_DT serum_NN samples_NNS by_IN type_NN 22F_JJ PS_NP absorption_NN ._SENT Accordingly_RB ,_, none_NN of_IN the_DT serum_NN samples_NNS had_VBD OPAs_NNS against_IN the_DT type_NN 1_CD strain_NN ._SENT Overall_RB ,_, the_DT sera_NN of_IN children_NNS with_IN contact_NN with_IN pneumococci_NNS of_IN a_DT homologous_JJ serotype_NN had_VBD OPA_NP (_( titers_NNS ,_, >=8_JJ )_) more_RBR often_RB than_IN the_DT sera_NN of_IN children_NNS without_IN homologous_JJ contact_NN (_( 20_CD of_IN 46_CD versus_CC 10_CD of_IN 68_CD for_IN the_DT pneumococcal_JJ serotype_NN contact-positive_NN versus_IN the_DT pneumococcal_JJ serotype_NN contact-negative_JJ groups_NNS combined_VBN ;_: Table_NP )_) ._SENT Furthermore_RB ,_, the_DT antibodies_NNS were_VBD more_JJR often_RB specific_JJ in_IN the_DT samples_NNS of_IN children_NNS with_IN contact_NN with_IN pneumococci_NNS of_IN the_DT homologous_JJ serotype_NN than_IN in_IN the_DT samples_NNS of_IN children_NNS without_IN contact_NN with_IN pneumococci_NNS of_IN the_DT homologous_JJ serotype_NN ._SENT Only_RB 3_CD of_IN the_DT 45_CD samples_NNS with_IN cross-reactive_JJ antibodies_NNS had_VBD OPAs_NP ,_, whereas_IN 27_CD of_IN the_DT 69_CD samples_NNS with_IN specific_JJ antibodies_NNS had_VBD OPAs_NP ._SENT Association_NP between_IN antibody_NN concentration_NN and_CC OPA_NP ._SENT |_SYM The_DT concentrations_NNS of_IN antibodies_NNS to_TO type_VB 6B_JJ ,_, 11A_NP ,_, 14_CD ,_, and_CC 23F_NP PSs_NP in_IN serum_NN measured_VBN by_IN the_DT conventional_JJ EIA_NP and_CC the_DT EIA_NP with_IN type_NN 22F_JJ PS_NP absorption_NN were_VBD compared_VBN to_TO the_DT OPAs_NP ._SENT For_IN these_DT analyses_NNS ,_, serum_NN samples_NNS in_IN the_DT pneumococcal_JJ serotype_NN contact-positive_JJ group_NN and_CC the_DT pneumococcal_JJ serotype_NN contact-negative_JJ group_NN were_VBD combined_VBN ._SENT Serotypes_NNS 1_CD and_CC 19F_NP were_VBD not_RB included_VBN because_IN no_DT OPAs_NP against_IN these_DT serotypes_NNS were_VBD detected_VBN ._SENT For_IN serotypes_NNS 6B_JJ and_CC 14_CD ,_, the_DT two_CD EIAs_NNS gave_VBD very_RB similar_JJ antibody_NN concentrations_NNS ,_, and_CC thus_RB ,_, the_DT type_NN of_IN EIA_NP did_VBD not_RB influence_VB the_DT association_NN of_IN concentration_NN and_CC OPA_NP ._SENT For_IN serotypes_NNS 11A_NP and_CC 23F_NP the_DT cross-reactive_JJ nonfunctional_JJ antibodies_NNS were_VBD markedly_RB inhibited_VBN by_IN type_NN 22F_NP PS_NP and_CC the_DT association_NN between_IN the_DT concentrations_NNS and_CC the_DT OPAs_NP of_IN antibodies_NNS was_VBD improved_VBN when_WRB EIA_NP with_IN the_DT type_NN 22F_JJ PS_NP absorption_NN step_NN was_VBD used_VBN to_TO determine_VB the_DT antibody_NN concentration_NN ._SENT FIG._NN 1_CD ._SENT |_SYM Association_NP between_IN IgG_NP concentration_NN (_( in_IN micrograms_NNS per_IN milliliter_NN )_) ,_, as_RB measured_VBN by_IN conventional_JJ EIA_NP or_CC by_IN EIA_NP with_IN type_NN 22F_JJ PS_NP absorption_NN ,_, and_CC OPAs_NP (_( as_IN titers_NNS )_) of_IN antibodies_NNS to_TO type_VB 6B_JJ ,_, 11A_NP ,_, 14_CD ,_, and_CC 23F_NP Pnc_NP PSs_NP ._SENT Association_NP between_IN IgG_NP concentration_NN (_( in_IN micrograms_NNS per_IN milliliter_NN )_) ,_, as_RB measured_VBN by_IN conventional_JJ EIA_NP or_CC by_IN EIA_NP with_IN type_NN 22F_JJ PS_NP absorption_NN ,_, and_CC OPAs_NP (_( as_IN titers_NNS )_) of_IN antibodies_NNS to_TO type_VB 6B_JJ ,_, 11A_NP ,_, 14_CD ,_, and_CC 23F_NP Pnc_NP PSs_NP ._SENT Serum_NP samples_NNS were_VBD taken_VBN from_IN unimmunized_JJ children_NNS at_IN 18_CD or_CC 24_CD months_NNS of_IN age_NN ._SENT Horizontal_JJ lines_NNS ,_, a_DT titer_NN of_IN 4_CD was_VBD given_VBN to_TO sera_NN with_IN undetectable_JJ OPA_NP ;_: vertical_JJ lines_NNS ,_, a_DT concentration_NN of_IN 1.0_CD mug/ml_NN was_VBD used_VBN as_IN a_DT cutoff_NN for_IN the_DT EIAs_NP ._SENT TABLE_NN 2_CD |_SYM Number_NP of_IN serum_NN samples_NNS with_IN levels_NNS of_IN inhibition_NN of_IN <20%_and 80_CD %_NN with_IN the_DT indicated_JJ homologous_JJ and_CC heterologous_JJ (_( type_NN 22F_NN )_) Pnc_NP PSs_NP ,_, GMCs_NP of_IN antibody_NN measured_VBN by_IN conventional_JJ EIA_NP or_CC EIA_NP with_IN type_NN 22F_JJ PS_NP absorption_NN ,_, and_CC GMOPAs_NP of_IN antibodies_NNS to_TO Pnc_NP PSs_NP 1_CD ,_, 6B_NP ,_, 11A,14_NP ,_, 19F_NP ,_, and_CC 23F_NN in_IN sera_NN of_IN unimmunized_JJ children_NNS in_IN the_DT different_JJ groups_NNS TABLE_NP 3_CD |_SYM Numbers_NP of_IN serum_NN samples_NNS taken_VBN at_IN 18_CD and_CC 24_CD months_NNS of_IN age_NN from_IN unimmunized_JJ children_NNS in_IN the_DT different_JJ groups_NNS containing_VBG either_DT specific_JJ or_CC cross-reactive_JJ antibodies_NNS to_TO type_NN 1_CD ,_, 6B_NP ,_, 11A_NP ,_, 14_CD ,_, 19F_NP ,_, and_CC 23F_NP Pnc_NP PSs_NP and_CC OPAs_NP of_IN the_DT samples_NNS We_PP have_VBP previously_RB studied_VBN the_DT natural_JJ development_NN of_IN antibodies_NNS to_TO Pnc_NP PSs_NP and_CC its_PP$ association_NN with_IN previous_JJ contacts_NNS with_IN pneumococci_NNS ,_, nasopharyngeal_JJ carriage_NN ,_, or_CC AOM_NP in_IN the_DT FinOM_NP Cohort_NP Study_NP population_NN ._SENT Previous_JJ contacts_NNS were_VBD associated_VBN with_IN increased_VBN concentrations_NNS of_IN antibodies_NNS to_TO the_DT homologous_JJ serotype_NN ,_, but_CC there_EX were_VBD serotype-specific_JJ differences_NNS ._SENT However_RB ,_, the_DT children_NNS developed_VBD low_JJ concentrations_NNS of_IN antibodies_NNS to_TO all_PDT the_DT Pnc_NP PS_NP types_NNS studied_VBD even_RB without_IN contact_NN with_IN the_DT homologous_JJ serotype_NN ._SENT The_DT reason_NN seems_VBZ to_TO be_VB the_DT fact_NN that_IN the_DT detection_NN of_IN antibodies_NNS to_TO Pnc_NP PSs_NP is_VBZ affected_VBN by_IN the_DT cross-reactivity_NN of_IN the_DT Pnc_NP PS_NP antigens_NNS used_VBN in_IN the_DT present_JJ EIA_NP ._SENT We_PP studied_VBD here_RB the_DT specificities_NNS and_CC functional_JJ activities_NNS ,_, as_RB measured_VBN by_IN opsonophagocytosis_NN assay_NN ,_, of_IN these_DT antibodies_NNS and_CC correlated_VBD these_DT characteristics_NNS with_IN culture-confirmed_JJ contacts_NNS with_IN pneumococci_NNS ._SENT We_PP also_RB evaluated_VBD the_DT possibility_NN of_IN using_VBG the_DT type_NN 22F_JJ PS_NP absorption_NN step_NN in_IN EIA_NP to_TO improve_VB the_DT specificity_NN ._SENT For_IN the_DT whole_JJ study_NN population_NN ,_, antibody_NN increases_NNS yielding_VBG >=1_JJ mug_NN of_IN antibodies_NNS per_IN ml_NN in_IN the_DT children_NNS without_IN contact_NN with_IN the_DT homologous_JJ serotype_NN were_VBD rare_JJ compared_VBN to_TO the_DT antibody_NN increases_NNS in_IN children_NNS with_IN contact_NN with_IN the_DT homologous_JJ serotype_NN :_: 20_CD versus_IN 29_CD %_NN for_IN serotype_NN 19F_NN and_CC 4_CD to_TO 9_CD %_NN versus_IN 11_CD to_TO 70_CD %_NN for_IN the_DT other_JJ five_CD serotypes_NNS studied_VBD ._SENT We_PP included_VBD in_IN this_DT study_NN serum_NN samples_NNS taken_VBN at_IN either_DT 18_CD or_CC 24_CD months_NNS of_IN age_NN ;_: these_DT ages_NNS of_IN sample_NN collection_NN were_VBD chosen_VBN to_TO exclude_VB maternal_JJ antibodies_NNS ._SENT Sera_NP were_VBD grouped_VBN according_VBG to_TO the_DT pneumococcal_JJ contacts_NNS that_IN the_DT children_NNS had_VBD had_VBN by_IN the_DT indicated_JJ age_NN ._SENT In_IN general_NN ,_, serum_NN samples_NNS from_IN children_NNS with_IN contact_NN with_IN a_DT homologous_JJ serotype_NN contained_VBD serotype-specific_JJ antibodies_NNS ._SENT Moreover_RB ,_, these_DT samples_NNS often_RB had_VBD OPAs_NP ,_, although_IN there_EX were_VBD clear_JJ serotype-specific_JJ differences_NNS ._SENT In_IN contrast_NN ,_, antibodies_NNS in_IN serum_NN samples_NNS from_IN children_NNS without_IN contacts_NNS with_IN a_DT homologous_JJ serotype_NN were_VBD mostly_RB cross-reactive_JJ and_CC infrequently_RB had_VBD OPAs_NP ._SENT Previous_JJ studies_NNS by_IN us_PP and_CC other_JJ investigators_NNS with_IN sera_NN from_IN adults_NNS have_VBP shown_VBN that_DT detection_NN of_IN antibody_NN to_TO serotype_VB 14_CD by_IN EIA_NP is_VBZ serotype_NN specific_JJ ,_, whereas_IN detection_NN of_IN antibody_NN to_TO the_DT other_JJ serotypes_NNS is_VBZ hampered_VBN by_IN cross-reactivity_NN ._SENT The_DT present_JJ data_NNS with_IN sera_NN from_IN a_DT pediatric_JJ population_NN confirm_VBP that_IN antibodies_NNS to_TO type_VB 14_CD PS_NP are_VBP highly_RB specific_JJ ._SENT All_DT serum_NN samples_NNS in_IN the_DT Pnc_NP 14+_JJ group_NN also_RB had_VBD OPA_NP against_IN type_NN 14_CD ._SENT In_IN contrast_NN ,_, only_RB a_DT few_JJ serum_NN samples_NNS in_IN the_DT Pnc_NP 14-_CD group_NN had_VBD OPA_NP against_IN type_NN 14_CD ._SENT This_DT is_VBZ interesting_JJ since_IN this_DT difference_NN in_IN OPA_NP between_IN the_DT Pnc_NP 14+_NP and_CC the_DT Pnc_NP 14-_CD groups_NNS cannot_MD be_VB explained_VBN by_IN differences_NNS in_IN antibody_NN concentrations_NNS or_CC antibody_NN specificity_NN ._SENT The_DT origins_NNS of_IN the_DT antibodies_NNS in_IN samples_NNS in_IN the_DT Pnc_NP 14-_CD group_NN are_VBP not_RB known_VBN ;_: the_DT antibodies_NNS were_VBD not_RB absorbed_VBN by_IN type_NN 22F_NP PS_NP ,_, and_CC in_IN a_DT few_JJ cases_NNS they_PP also_RB had_VBD OPA_NP ._SENT It_PP is_VBZ possible_JJ that_IN some_DT contacts_NNS with_IN pneumococci_NNS remained_VBD undetected_JJ or_CC that_IN the_DT children_NNS had_VBD had_VBN contacts_NNS with_IN bacteria_NNS with_IN PSs_NP similar_JJ to_TO type_NN 14_CD ,_, e.g._FW ,_, the_DT type_NN III_NP PS_NP from_IN group_NN B_NN streptococci_NNS ._SENT In_IN the_DT case_NN of_IN serotype_NN 14_CD ,_, the_DT increase_NN in_IN antibody_NN levels_NNS or_CC the_DT concentration_NN alone_RB was_VBD not_RB as_RB good_JJ a_DT marker_NN of_IN previous_JJ contact_NN with_IN type_NN 14_CD as_IN OPA_NP was_VBD ._SENT The_DT results_NNS of_IN the_DT present_JJ study_NN confirm_VBP that_IN the_DT Pnc_NP PS_NP type_NN 6B_JJ preparation_NN used_VBN here_RB and_CC in_IN our_PP$ previous_JJ studies_NNS (_( -_: )_) is_VBZ specific_JJ ._SENT However_RB ,_, although_IN the_DT specificities_NNS of_IN antibodies_NNS to_TO PS_NP 6B_NP were_VBD good_JJ in_IN both_CC the_DT Pnc_NP 6B+_JJ and_CC the_DT Pnc_NP 6B-_JJ groups_NNS ,_, only_RB a_DT few_JJ serum_NN samples_NNS had_VBD OPA_NP ._SENT This_DT may_MD be_VB due_JJ to_TO the_DT overall_JJ low_JJ antibody_NN concentrations_NNS that_WDT were_VBD insufficient_JJ for_IN detection_NN of_IN OPA_NP by_IN the_DT present_JJ opsonophagocytosis_NN assay_NN ._SENT A_DT previous_JJ contact_NN with_IN serotype_NP 6A_NP ,_, which_WDT is_VBZ cross-reactive_JJ with_IN 6B_JJ ,_, explained_VBD the_DT increases_NNS in_IN the_DT levels_NNS of_IN antibodies_NNS to_TO type_VB 6B_JJ PS_NP in_IN three_CD of_IN the_DT eight_CD serum_NN samples_NNS in_IN the_DT Pnc_NP 6B-_JJ group_NN ,_, and_CC in_IN two_CD of_IN the_DT three_CD samples_NNS the_DT antibodies_NNS specificities_NNS were_VBD high_JJ ._SENT However_RB ,_, the_DT antibodies_NNS in_IN these_DT three_CD samples_NNS had_VBD no_DT OPA_NP against_IN type_NN 6B_JJ ,_, despite_IN the_DT presence_NN of_IN anti-type_JJ 6B_JJ antibody_NN concentrations_NNS equal_JJ to_TO those_DT in_IN the_DT samples_NNS from_IN the_DT Pnc_NP 6B+_JJ group_NN showing_VBG OPA_NP ._SENT This_DT is_VBZ in_IN accordance_NN with_IN data_NNS showing_VBG that_IN antibodies_NNS to_TO type_NN 6A_NN elicited_VBN by_IN vaccines_NNS containing_VBG type_NN 6B_JJ may_MD not_RB be_VB functional_JJ against_IN type_NN 6A_JJ strains_NNS or_CC that_IN more_JJR antibodies_NNS to_TO type_VB 6B_JJ PS_NP are_VBP needed_VBN for_IN killing_VBG of_IN a_DT type_NN 6A_JJ strain_NN than_IN for_IN killing_VBG of_IN a_DT type_NN 6B_JJ strain_NN ._SENT Altogether_RB 26_CD serum_NN samples_NNS with_IN >=1_JJ mug_NN of_IN IgG_NP against_IN type_NN 19F_NP PS_NP per_IN ml_NN ,_, as_RB detected_VBN by_IN the_DT conventional_JJ EIA_NP ,_, were_VBD analyzed_VBN ,_, and_CC none_NN of_IN these_DT serum_NN samples_NNS had_VBD OPA_NP against_IN type_NN 19F_NN ._SENT The_DT specificities_NNS of_IN the_DT antibodies_NNS in_IN samples_NNS from_IN children_NNS without_IN previous_JJ contact_NN with_IN type_NN 19F_NN were_VBD poor_JJ ._SENT However_RB ,_, despite_IN the_DT higher_JJR concentrations_NNS and_CC better_JJR specificities_NNS of_IN antibodies_NNS in_IN sera_NN from_IN children_NNS with_IN cultures_NNS positive_JJ for_IN type_NN 19F_NN ,_, the_DT sera_NN showed_VBD no_DT OPA_NP ._SENT The_DT specificities_NNS of_IN antibodies_NNS to_TO type_NN 19F_NN ,_, as_RB determined_VBN by_IN EIA_NP ,_, in_IN general_JJ ,_, were_VBD confusing_JJ ;_: in_IN some_DT cases_NNS antibody_NN binding_NN could_MD not_RB be_VB inhibited_VBN by_IN either_CC the_DT homologous_JJ PS_NP or_CC the_DT heterologous_JJ PS_NP ._SENT Furthermore_RB ,_, high_JJ concentrations_NNS of_IN antibodies_NNS to_TO type_NN 19F_NP PS_NP even_RB in_IN the_DT sera_NN of_IN vaccinated_VBN children_NNS do_VBP not_RB seem_VB to_TO offer_VB protection_NN against_IN AOM_NP ._SENT Also_RB ,_, higher_JJR anti-type_NN 19F_NN antibody_NN concentrations_NNS than_IN anti-type_JJ 6B_JJ antibody_NN concentrations_NNS are_VBP needed_VBN in_IN the_DT sera_NN of_IN vaccinated_VBN children_NNS for_IN OPA_NP ._SENT We_PP have_VBP previously_RB described_VBN that_IN antibodies_NNS to_TO type_VB 1_CD PS_NP can_MD be_VB detected_VBN by_IN conventional_JJ EIA_NP in_IN serum_NN samples_NNS of_IN children_NNS participating_VBG in_IN the_DT FinOM_NP Cohort_NP Study_NP ,_, even_RB though_IN type_NN 1_CD pneumococcus_NN was_VBD not_RB detected_VBN in_IN any_DT of_IN the_DT NP_NP ,_, NPA_NP ,_, or_CC MEF_NP samples_NNS during_IN the_DT study_NN ._SENT We_PP have_VBP now_RB shown_VBN that_IN these_DT antibodies_NNS are_VBP not_RB specific_JJ for_IN type_NN 1_CD PS_NP and_CC therefore_RB are_VBP probably_RB produced_VBN by_IN a_DT non-type-specific_JJ antigenic_JJ stimulus_NN ._SENT These_DT antibodies_NNS possessed_VBD no_DT OPA_NP against_IN type_NN 1_CD pneumococci_NNS ._SENT Use_NN of_IN the_DT type_NN 22F_JJ PS_NP absorption_NN step_NN in_IN the_DT EIA_NP removed_VBD all_DT antibodies_NNS to_TO type_VB 1_CD PS_NP detected_VBD by_IN the_DT conventional_JJ EIA_NP in_IN all_DT samples_NNS ._SENT The_DT data_NNS obtained_VBN in_IN this_DT study_NN highlight_VB the_DT need_NN for_IN heterologous_JJ type_NN PS_NP absorption_NN in_IN EIA_NP ,_, especially_RB when_WRB samples_NNS from_IN an_DT unimmunized_JJ population_NN are_VBP studied_VBN ._SENT Type_NN 22F_JJ PS_NP absorption_NN did_VBD not_RB have_VB a_DT notable_JJ effect_NN on_IN the_DT concentrations_NNS of_IN antibodies_NNS to_TO type_VB 6B_JJ and_CC type_NN 14_CD Pnc_NP PSs_NP ._SENT However_RB ,_, the_DT type_NN 6B_JJ antigen_NN was_VBD especially_RB chosen_VBN for_IN this_DT study_NN ,_, and_CC the_DT commercially_RB available_JJ preparations_NNS seem_VBP to_TO be_VB more_RBR cross-reactive_JJ ,_, indicating_VBG that_IN ,_, in_IN general_NN ,_, the_DT type_NN 22F_JJ PS_NP absorption_NN step_NN is_VBZ also_RB needed_VBN for_IN the_DT anti-type_NN 6B_JJ EIA_NP ._SENT Because_IN the_DT nature_NN of_IN the_DT cross-reactivity_NN is_VBZ unknown_JJ ,_, the_DT specificity_NN and_CC amount_NN of_IN antibodies_NNS inhibited_VBN by_IN type_NN 22F_NP PS_NP cannot_MD be_VB determined_VBN ._SENT It_PP is_VBZ ,_, however_RB ,_, probable_JJ that_IN the_DT antibodies_NNS removed_VBN are_VBP not_RB serotype_JJ specific_JJ and_CC ,_, in_IN principle_NN ,_, should_MD not_RB be_VB detected_VBN ._SENT Data_NNS from_IN us_PP and_CC others_NNS show_VBP that_IN the_DT type_NN 22F_JJ PS_NP absorption_NN step_NN increases_VBZ the_DT association_NN between_IN the_DT antibody_NN concentration_NN obtained_VBN by_IN EIA_NP and_CC OPA_NP ._SENT Furthermore_RB ,_, the_DT results_NNS of_IN the_DT present_JJ study_NN suggest_VBP that_IN if_IN antibody_NN detection_NN by_IN EIA_NP is_VBZ used_VBN to_TO study_VB the_DT seroepidemiology_NN of_IN pneumococcal_JJ infections_NNS ,_, an_DT EIA_NP with_IN type_NN 22F_JJ PS_NP absorption_NN instead_RB of_IN the_DT conventional_JJ EIA_NP is_VBZ highly_RB recommended_VBN ._SENT The_DT present_JJ opsonophagocytosis_NN assay_NN requires_VBZ approximately_RB 1_CD mug_NN of_IN antibody_NN per_IN ml_NN for_IN detection_NN of_IN OPA_NP in_IN the_DT sera_NN of_IN immunized_VBN infants_NNS ._SENT As_RB shown_VBN here_RB ,_, the_DT concentration_NN of_IN specific_JJ antibodies_NNS needed_VBN may_MD be_VB even_RB higher_JJR in_IN sera_NN of_IN unimmunized_JJ children_NNS and_CC may_MD be_VB different_JJ for_IN the_DT different_JJ serotypes_NNS ._SENT In_IN the_DT present_JJ study_NN ,_, high_JJ concentrations_NNS of_IN specific_JJ antibodies_NNS to_TO type_VB 11A_NP and_CC 19F_NP PSs_NP were_VBD insufficient_JJ for_IN OPA_NP ,_, while_IN lower_JJR concentrations_NNS were_VBD associated_VBN with_IN OPA_NP against_IN type_NN 14_CD and_CC 23F_JJ strains_NNS ._SENT It_PP is_VBZ possible_JJ that_IN in_IN addition_NN to_TO the_DT antibody_NN concentration_NN and_CC specificity_NN ,_, other_JJ qualitative_JJ characteristics_NNS of_IN the_DT antibodies_NNS ,_, e.g._FW ,_, antibody_NN avidity_NN ,_, affect_VB OPA_NP ._SENT Contacts_NNS with_IN pneumococci_NNS seem_VBP to_TO elicit_VB the_DT development_NN of_IN specific_JJ and_CC functional_JJ antibodies_NNS ,_, and_CC thus_RB ,_, detection_NN of_IN OPA_NP in_IN sera_NN could_MD be_VB an_DT indicator_NN of_IN a_DT serotype-specific_JJ pneumococcal_JJ contact_NN ._SENT However_RB ,_, the_DT sensitivity_NN of_IN the_DT assay_NN for_IN OPA_NP described_VBN here_RB should_MD be_VB improved_VBN to_TO detect_VB activity_NN in_IN the_DT sera_NN of_IN unimmunized_JJ individuals_NNS ._SENT 